Facing lenalidomide-refractory myeloma

摘要

In this issue of Blood, Mikhael et al report the results of a phase 1b study of isatuximab combined with standard-dose pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) who had received >= 2 prior lines of treatment that included lenalidomide and a proteasome inhibitor (PI).